Alnylam Pharmaceuticals, Inc. (LON:0HD2)

London flag London · Delayed Price · Currency is GBP · Price in USD
396.66
+4.58 (1.17%)
At close: Aug 1, 2025
1.17%
Market Cap39.76B
Revenue (ttm)1.80B
Net Income (ttm)-232.90M
Shares Outn/a
EPS (ttm)-1.80
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume123
Average Volume120
Open383.95
Previous Close392.07
Day's Range380.00 - 398.92
52-Week Range209.75 - 401.66
Betan/a
RSI82.46
Earnings DateAug 7, 2025

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clin... [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
Founded 2002
Employees 2,230
Stock Exchange London Stock Exchange
Ticker Symbol 0HD2
Full Company Profile

Financial Performance

In 2024, Alnylam Pharmaceuticals's revenue was $2.25 billion, an increase of 22.97% compared to the previous year's $1.83 billion. Losses were -$278.16 million, -36.82% less than in 2023.

Financial numbers in USD Financial Statements

News

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...

18 hours ago - CNBC Television

President Trump demands drugmakers slash prices within 60 days

CNBC's Joe Kernen reports on the latest news.

20 hours ago - CNBC Television

Alnylam Pharmaceuticals Q2 Earnings Crush Estimates, Stock Hits 52-Week High On Upbeat Forecast

The biotechnology sector is witnessing a surge in investor optimism as companies like Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) continue to outperform market expectations. Amid a backdrop of growin...

1 day ago - Benzinga

Alnylam Pharmaceuticals Q2 Earnings Crush Estimates, Stock Hits 52-Week High On Upbeat Forecast

The biotechnology sector is witnessing a surge in investor optimism as companies like Alnylam Pharmaceuticals Inc. ALNY continue to outperform market expectations. Amid a backdrop of growing demand fo...

1 day ago - Benzinga

Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended J...

1 day ago - Business Wire

Here's How Much $100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth Today

Alnylam Pharmaceuticals (NASDAQ: ALNY) has outperformed the market over the past 15 years by 10.3% on an annualized basis producing an average annual return of 22.67%. Currently, Alnylam Pharmaceutic...

9 days ago - Benzinga

Five years after COVID, pharma shares languish in US policy limbo

Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares remain in the doldrums, highlighting uncertainty over drug pricing policies...

9 days ago - Reuters

This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag...

11 days ago - Benzinga

Alnylam to Webcast Conference Call Discussing Second Quarter 2025 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter end...

15 days ago - Business Wire

Alnylam Pharma Stock Outlook: Is ALNY Topping Out?

Alnylam Pharmaceuticals (NASDAQ: ALNY) is currently in Phase 10 of its 18-phase Adhishthana Cycle. With this phase scheduled to end in September 2025, the stock remains within its bullish structure. ...

4 weeks ago - Benzinga

Alnylam Pharma Stock Outlook: Is ALNY Topping Out?

Alnylam Pharmaceuticals ALNY is currently in Phase 10 of its 18-phase Adhishthana Cycle. With this phase scheduled to end in September 2025, the stock remains within its bullish structure.

4 weeks ago - Benzinga

Alnylam Pharmaceuticals Names Garg R&D Chief

Alnylam Pharmaceuticals named Pushkal Garg executive vice president and chief research and development officer.

6 weeks ago - Market Watch

Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that Pushkal Garg, M.D., has been appointed E...

6 weeks ago - Business Wire

Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the European Commission (EC) has granted...

7 weeks ago - Business Wire

Moderna Beats Alnylam Appeal In COVID Vaccine Patent Case

The U.S. Court of Appeals for the Federal Circuit (CAFC) on Wednesday affirmed a district court’s finding of noninfringement in favor of Moderna, Inc. (NASDAQ: MRNA) in its ongoing patent battle with...

2 months ago - Benzinga

Why Alnylam Could Outperform In The Transthyretin Amyloidosis With Cardiomyopathy Field

Vutrisiran, recently FDA-approved for ATTR-CM, offers strong efficacy and a favorable safety profile compared to competitors. See why I rate ALNY stock a Hold.

2 months ago - Seeking Alpha

Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Goldman S...

2 months ago - Business Wire

Here's How Much $1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth Today

Alnylam Pharmaceuticals (NASDAQ: ALNY) has outperformed the market over the past 20 years by 12.14% on an annualized basis producing an average annual return of 20.3%. Currently, Alnylam Pharmaceutic...

2 months ago - Benzinga

Alnylam Issues 2024 Corporate Responsibility Report

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the publication of its 2024 Corporate Responsibility Report. Gui...

2 months ago - Business Wire

AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today presented the most contemporary analysis of the HELIOS-B Phase 3 study of ...

2 months ago - Business Wire